Milagros Reyes
Internal Medicine · Detroit, MINPI 1386684843
Payments from drug & device makers
Across 497 payments — averaging $23.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$5K
- Viiv Healthcare Company$4K
- Merck$1K
- Janssen Products, LP$662
- AbbVie$588
- Johnson & Johnson$347
- plus $443 from 9 others
What the payments were for
- Food & beverage$11,33198%
- Education$2422%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 192 | $4,750 |
| Viiv Healthcare Company | 189 | $3,586 |
| Merck | 47 | $1,197 |
| Janssen Products, LP | 8 | $662 |
| AbbVie | 24 | $588 |
| Johnson & Johnson | 20 | $347 |
| Alnylam Pharmaceuticals Inc. | 1 | $139 |
| Pfizer | 6 | $130 |
| Janssen Scientific Affairs, LLC | 2 | $52 |
| Cardiovascular Systems Inc. | 2 | $39 |
| EMD Serono, Inc. | 2 | $22 |
| Napo Pharmaceuticals Inc | 1 | $18 |
| Qiagen, LLC | 1 | $16 |
| Phadia US Inc. | 1 | $14 |
| Theratechnologies Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,573 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 35 | $138,496 |
| DovatoDolutegravir Sodium/Lamivudine | 11 | $32,216 |
| TivicayDolutegravir Sodium | 14 | $31,240 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $25,992 |
| Pravastatin Sodium | 18 | $104 |
| Alprazolam | 20 | $81 |
| Atorvastatin Calcium | 12 | $57 |
| Triamcinolone Acetonide | 12 | $43 |
| ValacyclovirValacyclovir Hcl | 11 | $34 |
| Amlodipine Besylate | 16 | $22 |
| Metformin Hcl | 13 | $17 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $4,750 | $164,48847 claims |
| Viiv Healthcare CompanyDovato, Tivicay | $3,586 | $63,45625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Detroit
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Rana BalboulDetroit$2.4M
- Philip KuriakoseDetroit$1.9M
- Erlene SeymourDetroit$797K
- Sheela TejwaniDetroit$712K
- Vrushali DabakDetroit$509K
- James McCordDetroit$493K
- Saroj NeupaneDetroit$487K
- David StocktonDetroit$402K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.